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Determination of Inhibitor Specificity for Low Molecular Weight
Protein Tyrosine Phosphatase Isoforms A and B
Erica K. Sinner, Edward J. McIntee, and Henry V. Jakubowski
Department of Chemistry, College of Saint Benedict | Saint John’s University, St. Joseph, MN, 56374
ABSTRACT
The two active isoforms of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) have
inverse cellular effects on cancer. Isoform A has been found to be anti-oncogenic, while
overexpression of Isoform B is oncogenic. Inhibitors of Isoform B could have anti-cancer effects,
however, it is of utmost importance that these inhibitors exhibit specificity for Isoform B and do not
affect the function of Isoform A. Isoform A was recombinantly expressed, purified and
characterized in order to compare its structure and function to Isoform B. It is hoped that this
characterization, along with the synthesis and screening of potential inhibitors for both isoforms,
will streamline the discovery and optimization of new anti-cancer candidates that specifically target
LMW-PTP Isoform B.
INTRODUCTION
In humans, there are over 100 known
Protein Tyrosine Phosphatases (PTPs), which
play many different regulatory roles in
cellular growth, proliferation, motility, and
gene expression1. There are four types of
PTPs, and though they all have a similar
catalytic phosphate binding loop, they are
otherwise structurally different2.
The
smallest of this group, the Low Molecular
Weight Protein Tyrosine Phosphatases
(LMW-PTPs), are 18 kD soluble proteins that
are involved in the regulation and control of
several signal transducers that modulate cell
growth and proliferation such as platelet
derived growth factor receptor (PDGFR),
epidermal growth factor (EGF), and EphrinA2 receptor (EPHA2). Because of this
participation in tumorigenic pathways,
overexpression of LMW-PTP is indicative of
the onset and proliferation of aggressive
tumors in breast, colon, bladder, and kidney
cancers in humans1. These cancers exhibit
invasive properties and migrate from their
origin to other tissues, causing widespread

damage. In addition, studies have shown that
over-expression of LMW-PTP aids in the
transition of cells from healthy to cancerous3.
There are two active isoforms of LMW-PTP
(isoforms A and B) expressed through
alternative splicing of the ACP1 gene, which,
as shown in figure 1, differ structurally only
by a loop flanking the active site1. Recently it
has been shown that the two human isoforms
of LMW-PTP have different effects on tumor
growth. Isoform A has been shown to have
anti-oncogenic properties, whereas Isoform B
has been shown to be oncogenic5. New
specific inhibitors of Isoform B that do not
affect the activity of Isoform A could
potentially be used treat and prevent the
spread of cancer. In addition, many small
molecules have been tested for inhibition of
Isoform B, but their effect on Isoform A is
unknown. Therefore, further characterization
of the nuanced differences between the two
isoforms could streamline the discovery and
optimization of potential anti-cancer agents
that specifically target LMW-PTP Isoform B.
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shown in Figure 2, were identified as effective
LMW-PTP inhibitors4.
Pyridoxal- 5’Phosphonate and its analogs are good
candidates because of the stronger, nonhydrolysable carbon-phosphorus bond4. If
these phosphonate inhibitors strongly inhibit
Isoform B while leaving Isoform A unaffected,
they could be potential anti-cancer drug
candidates.

b
Figure 2. Comparison of PLP and potential
inhibitor, Pyridoxal 5’-Phosphonate.

Figure 1. Crystal structures of LMW-PTP:
(a) Isoform A (PDB entry 5PNT); (b) Isoform
B (PDB entry 1XWW).
Pyridoxal-5’-Phosphate (PLP), the active
form of Vitamin B6, effectively inhibits LMWPTP Isoform B, but it has numerous cellular
roles, such as acting as a cofactor of many
enzymes. This lack of specificity makes it an
impractical candidate for targeting LMW-PTP.
In addition to PLP’s lack of selectivity, it is a
poor substrate of LMW-PTP because the
phosphorus-oxygen bond is easily hydrolyzed
by many enzymes present in the cellular
environment,
leading
to
limited
bioavailability.
Using molecular docking
software Maestro (Schroedinger, LLC),
Pyridoxal 5’-Phosphonate and its analogs,
which exhibit similar properties to PLP as

The specificity of inhibitors needs to be
evaluated by comparative assays of the two
isoforms.
Isoform B was previously
expressed and many small molecules have
been assessed for inhibitory properties.
However, no assays have been done with
Isoform A, so the specificity of the tested
inhibitors is unknown. In order to correct
this, Isoform A was expressed, purified, and
refolded to yield active enzyme. This makes
the Isoform A comparison assays possible,
which will lead to a better understanding of
the small molecule properties that provide
the best specificity for Isoform B.
RESULTS AND DISCUSSION
Expression and Characterization of
Isoform A. A pEx expression vector with an
amino-terminal polyhistidine tag and
synthetic ACP1 mRNA variant 3 gene was
obtained from Blue Heron Biotech, LLC, and
expressed in BL21 competent E. coli.
Induction of expression was successful and
the protein was purified using a Ni-NTA
affinity column. The resulting protein was
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Figure 3. (a) SDS-PAGE analysis of LMW-PTP
Isoform A expressed with N-terminal
polyhistidine tag. Lane 1 contains protein
that did not bind to the column and came
through with wash buffer (20 mM Tris, 0.3 M
NaCl, 25 mM imidazole), lane 2 contains
Precision Plus Protein Dual Color Standard
(Bio-Rad), and lane 3 contains protein eluted
from the column with elution buffer (20 mM
Tris, 0.3 M NaCl, 0.25 M imidazole); (b)
Enzyme activity assay results for Nterminally tagged Isoform A (Concentration
of 1 = 0.11 mg/mL).
analyzed by SDS-PAGE, and the molecular
weight was determined to be approximately
19 kD (Figure 3a). Enzymatic activity was
then assessed by an in vitro assay that was
developed to measure inhibitory properties
of small molecules on Isoform B. The

Figure 4. (a) SDS-PAGE analysis of LMW-PTP
Isoform A expressed with C-terminal
polyhistidine tag Lane 1 contains protein that
did not bind to the column and came through
with wash buffer (20 mM Tris, 0.3 M NaCl, 25
mM imidazole), Precision Plus Protein Dual
Color Standard (Bio-Rad), and lane 3 contains
protein eluted from the column with elution
buffer (20 mM Tris, 0.3 M NaCl, 0.25 M
imidazole); (b) Enzyme activity assay results
for
C-terminally
tagged
Isoform
A
(Concentration of 1 is approximately 0.01
mg/mL ).
substrate used in this assay is p-nitrophenyl
phosphate, which is enzymatically hydrolyzed
to form the product p-nitrophenol, which,
when placed in a basic environment, can be
detected by absorbance spectroscopy at 405
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nm. This substrate is reportedly compatible
with Isoform A5.
However, when the
recombinant Isoform A was assayed, no
activity was observed (Figure 3b).
Since the affinity tag was potentially
interfering with protein folding during
translation, a new pEx vector with a carboxyterminal polyhistidine tag was obtained and
expressed in the same conditions as the
amino-terminal vector. However, as shown in
Figure 4a, the protein was not as robustly
expressed. It was determined through SDSPAGE analysis that the purified protein had a
molecular weight of approximately 30, which
is far from the expected molecular weight of
18 kD. The C-terminally tagged protein was
then assayed, and once again showed no
activity, as shown in Figure 4b.
As moving the affinity tag to the C-terminal
end of the protein did not yield active protein,
refolding of the protein was attempted. The
N- terminally tagged Isoform A was used

since its expression was more reliable and the
molecular weight was much nearer to the
expected value. The protein was purified in
denaturing conditions (6M guanidine) and
subjected to nine different conditions with
differing levels of the denaturants guanidine
and L-arginine as well as differing redox
environments. The results of this experiment
are shown in Table 1. Refolding of Isoform A
measured by recovery of activity in the assay
described above was most effectively
achieved by a reduced to oxidized glutathione
ratio of 10:1 and 0.48 M guanidine. Control
experiments were run on Isoform B, which
was previously expressed as a glutathione Stransferase (GST) fusion protein, to verify
whether refolding conditions interfered with
the activity assay. The buffer conditions did
not appear to interfere, as Isoform B showed
trends very similar to Isoform A in refolding
behavior (Table 1).

Table 1. The effect of denaturant and redox conditions on protein refolding measured by recovery
of activity (significant recovery denoted by +, modest recovery by 0, and no recovery by -). All
buffer conditions also contained 1 mM EDTA, 50 mM Tris, 20 mM NaCl, and 0.8 mM KCl.
Reduced
Oxidized
Buffer
Guanidine
L-Arginine
Isoform A
Isoform B
Glutathione
Glutathione
Condition
(M)
(M)
Refolding
Refolding
(mM)
(mM)
1
2
3
4
5
6
7
8
9

0.48
0.48
0.48
0.98
0.98
0.98
1.48
1.48
1.48

0
0.4
0.8
0
0.4
0.8
0
0.4
0.8

Synthesis of inhibitors. Previous in silico
docking
experiments
using
Maestro
(Schroedinger, LLC) identified pyridoxal 5’

20
20
10
20
10
20
10
20
20

2
4
10
4
10
2
10
2
4

+
+
0
0
0
0
-

+
+
0
0
0
0
-

phosphonate and its analogs as good inhibitor
candidates.
They are being synthesized
through the synthetic scheme shown in figure
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Figure 5. Synthetic scheme for target phosphonate analogs.
5. The addition of the protection group to
yield intermediate A was unsuccessful unless

everything was completely anhydrous. After
distillation of the acetone and 2, 2- dimethoxy
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propane, and vacuum drying of the
pyridoxine and p-toluenesulfonic acid,
intermediate A was formed with good yield
and verified through 1H NMR. The oxidation
of A to B catalyzed by pyridinium
chlorochromate was fairly successful as
indicated by the appearance of an aldehyde
peak (10.03 ppm) on a scale less than or
equal to 1 gram, but was difficult to scale up.
Increased purity of intermediate A led to
increased yield of intermediate B. Tetraethylmethylene diphosphonate was then used in a
Horner-Wittig reaction to form C, which was
effectively purified using a silica gel column
with a water/methanol/ethyl acetate
v/v=1/10/89 mobile phase. Both E and Z
isomers were formed, but since it is desirable
for both the alkane and alkene analogs to be
synthesized and tested for inhibitory activity
in both isoforms of LMW-PTP, the fractions
that were not isomerically pure were saved
for hydrogenation. The removal of the
isopropylidene
protecting group was
achieved through reflux with hydrochloric
acid in methanol, though in later trials
removal of intermediate D was required
several times to shift the equilibrium and get
an acceptable yield.
Deprotection of the
phosphonate to form compound 1 was
difficult due to very limited solubility of
intermediate D in dichloromethane. Several
other solvents were tested, and solubility was
very low in all of the solvents compatible with
the reactions. Since it was suspected that the
pyridyl
nitrogen
had
formed
the
hydrochloride salt, conversion to the basic
form was attempted with sodium hydride, but
was not successful.
The oxidation of the
second alcohol to form intermediate E was
attempted using the same procedure as the
oxidation to form intermediate B. Due to the
increased polarity of the compound, it was
not possible to extract it from the aqueous

layer. The water was therefore removed
from the sample on a speedvac in an attempt
to isolate the product. However, formation of
the aldehyde was not verified either by 1H
NMR
or
testing
with
2,
4dinitrophenylhydrazine. Once the conditions
for the synthesis and purification of
compounds 1 and 2 are optimized, the
hydrogenation of C to F will be performed,
and the same conditions will be used to
obtain compounds 3 and 4.
CONCLUSION
The expression of LMW-PTP Isoform A and
the subsequent refolding procedure allows
for production of the active form of the
enzyme. This procedure needs to be scaled
up before it is a viable method of procuring
active Isoform A. Once a larger scale method
is optimized, further characterization of this
protein, such as the acquisition of circular
dichroism (CD) data, will need to be done.
This characterization, as well as a detailed
comparison to Isoform B, will further
streamline the process of finding good,
selective inhibitors for Isoform B. Once active
Isoform A is produced on a larger scale, all
the small molecules previously tested on
Isoform B can be tested for inhibition of
Isoform A. In addition, once the synthesis of
the phosphonate analogs of PLP is complete,
they can be tested for inhibition of both
isoforms. The results of these assays will help
to identify structural motifs that impart
inhibitor specificity for one isoform over the
other, which will simplify the process of
developing effective anti-cancer agents that
target LMW-PTP Isoform B.
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EXPERIMENTAL
Introduction of plasmid into cells. The
pEx expression vector (0.1 µL, 50.1 ng/µL)
obtained from Blue Heron Biotechnology,
LLC, was added to BL21 competent E. coli
cells (New England BioLabs) and incubated
on ice for 30 minutes. The cells were then
heat shocked at 42°C for 10 seconds, followed
by incubation on ice for 5 minutes.
Subsequently, 900 µL of cold SOC medium
was added and incubated at 37°C with 225
rpm shaking for 1 hour. Cells (100 µL, 1X and
0.1X) were plated on LB/ampicillin agar
plates and incubated at 37°C for 18 hours.
Protein expression. One colony from the
plates from the above step was inoculated
into each of 4 sterile aliquots of LB media (5
mL) to which ampicillin (10 µL, 50 mg/mL)
had been freshly added. The cells were then
grown in liquid culture at 37°C with 225 rpm
shaking for 18 hours. Cells were then
archived in 40% glycerol solution and stored
at -80°C. The glycerol stock was then grown
in liquid culture as previously described. The
liquid culture (2 mL) was added to each of 5
aliquots of sterile LB (200 mL) to which
ampicillin (400 µL, 50 mg/mL) was freshly
added. The aliquots were then incubated at
37°C with 225 rpm shaking for 4 hours.
Absorbance at 600 nm was used to monitor
cell growth, and isopropylthio-D-galactoside
(IPTG; 200 µL, 24 mg/mL) was added to each
aliquot when A600 reached 0.4 to induce
protein expression.
The aliquots were

incubated at 37°C with 225 rpm shaking for 3
hours, followed by centrifugation at 5000X g
for 10 minutes.
The pellet was then
isolated and resuspended in B-PER Bacterial
protein
extraction
reagent
(Thermo
Scientific) at 4 mL per gram of cell pellet. The
suspension was incubated at room
temperature for 15 minutes before being
centrifuged at 15000X g for 5 minutes. The
soluble protein was then isolated and stored
at -80°C.
Purification of protein.
The soluble
protein extract described above was purified
using Ni-NTA resin (Thermo Scientific).
Sample was loaded in 1:1 equilibration buffer
(20 mM TRIS, 0.3 M NaCl, 10 mM Imidazole,
pH 10.0). The column was washed with wash
buffer (20 mM TRIS, 0.3 M NaCl, 25 mM
Imidazole, pH 10.0) until A280 reached
baseline. Protein was eluted with elution
buffer (20 mM TRIS, 0.3 M NaCl, 0.25 M
Imidazole, pH 10.25) and analyzed for purity
and molecular weight through SDS-PAGE.
Purification of protein in denaturing
conditions. Protein was purified as described
above except with 6 M GuHCl present in each
buffer.
Enzyme activity assay. E-pure water (180
µL), 1.0 M sodium acetate/acetic acid buffer
solution (25 µL), and 50 mM p-nitrophenyl
phosphate (25 µL) were added to 0.5 mL
microcentrifuge tubes and mixed well. The
protein being assayed (20 µL) was then
added at timed intervals and incubated for 30
minutes. The reaction was quenched by
transferring 20 µL of the reaction mixture to a
well of a 96 well plate containing 100 µL of
0.5 M KOH. Absorbance was then measured
at 405 nm.
Refolding assay. Protein purified in
denaturing conditions was added in 20 µL
increments to each of 9 tubes containing 10
mM EDTA and differing amounts of
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guanidine, L-arginine, reduced glutathione,
and oxidized glutathione followed by
incubation at 4°C for 24 hours. Buffers were
obtained from Pierce Biotechnology, Inc.
Activity was assessed in the same manner
described above except the reaction was run
for 18 hours instead of 30 minutes due lower
protein concentration.
Synthesis of 3, 4’-o-isopropylidene
pyridoxine (A). Distilled acetone (60 mL),
distilled 2, 2-dimethoxy propane (40 mL), and
vacuum dried pyridoxine HCl (4 g, 19.52
mmol) was added to a 250 mL round bottom
flask containing p-toluenesulfonic acid (13.24
g, 78.08 mmol) that had been dried at 115°C
on a kugelrohr vacuum distillation apparatus
for 6 hours. The yellow-orange suspension
that formed was stirred for 24 hours at room
temperature in a dry environment
maintained by a calcium carbonate filled
drying tube. The reaction mixture, now dark
brown, was neutralized by solid sodium
bicarbonate, filtered, and concentrated. The
remaining dark brown solid was dissolved in
brine (8 mL) and extracted with
dichloromethane. The organic fractions were
washed with water and dried over sodium
sulfate, and concentrated. The cream colored
solid product (2.748 g, 68.7%) was
recrystallized by dissolution in ethanol
followed by precipitation by the addition of
cold diethyl ether. 1H NMR (CDCl3, 400 MHz):
δ (ppm) 7.84 (s, 1H), 4.93 (s, 2H), 4.55 (s, 2H),
2.37(s, 3H), 1.54 (s, 6H).
Synthesis
of
2,2,8-trimethyl-4H[1,3]dioxino[4,5-c]pyridine-5carbaldehyde (B). Compound A (1.0 g, 4.8
mmol), pyridinium chlorochromate ( 1.03 g,
4.8 mmol), and pyridine (14 mL) were added
to a 25 mL round bottom flask and refluxed at
115°C for 90 minutes. After the reaction
mixture had cooled to room temperature,
diethyl ether (35 mL) was added. The black

precipitate that formed was then filtered off,
and the filtrate was then washed with water.
The organic fractions were dried with sodium
sulfate and concentrated to give a brown oil
(0.504 g, 50.4%). 1H NMR (CDCl3, 400 MHz):
δ (ppm) 10.03 (s, 1H), 8.46 (s, 1H), 5.17 (s,
2H), 2.50 (s, 3H), 1.56 (s, 6H).
Synthesis of diethyl (E)-(2-(2,2,8trimethyl-4H-[1,3]dioxino[4,5-c]pyridin5-yl)vinyl)phosphonate (C).
Lithium
diisopropylamide (1 M in THF, 1.5 mL) in a 25
mL round bottom was cooled to -78°C in a dry
ice/acetone bath in a nitrogen environment.
Tetraethyl-methylenediphosphonate
(0.66
mL, 2.65 mmol) was mixed with
tetrahydrofuran (3 mL) and added to the
flask and the mixture was stirred for 1 hour.
Compound B (0.5 g, 2.414 mmol) was
dissolved in 6 mL tetrahydrofuran and added
to the flask, followed by stirring for 45
minutes. The reaction mixture was then
allowed to slowly warm to room
temperature, and it was then refluxed for 2
hours at 100°C. After cooling to room
temperature, the reaction was quenched with
saturated aqueous ammonium chloride
followed by extraction with diethyl ether.
The organic fractions were then dried with
sodium sulfate, filtered and concentrated to
give yellow oil. Purification of crude product
was
done
by
silica
gel
column
chromatography (1 x 20 cm, 63-200 mesh
silica gel, eluent: water/methanol/ethyl
acetate, v/v=1/10/89) to give pure product C
(0.385 g, 77%). 1H NMR (CDCl3, 400 MHz): δ
(ppm) 8.23 (s, 1H), 7.30 (dd, 1H), 6.21 (t, 1H),
4.90 (s, 2H), 4.14 (quint, 4H), 2.43 (s, 3H),
1.55 (s, 6H), 1.36 (t, 6H).
Synthesis of diethyl (E)-(2-(5-hydroxy-4(hydroxymethyl)-6-methylpyridin-3yl)vinyl)phosphonate (D). Compound C
(.327 g, 9.59 mmol) was dissolved in
methanol (0.5 mL) and added to a 25 mL
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round bottom flask. Hydrochloric acid (4 mL,
1.25 M in methanol) was added to the flask
followed by reflux for 2 hours at 60°C. The
reaction mixture was neutralized with solid
sodium
bicarbonate,
filtered,
and
concentrated. The resulting sticky brown
substance was washed with diethyl ether to
yield product D (.267 g, 81.6%). 1H NMR
(D2O, 400 MHz): δ (ppm) 7.79 (s, 1H), 7.62
(dd, 1H), 6.32 (t, 1H) 4.74 (s, 2H), 4.06 (quint,
4H), 2.34 (s, 3H), 1.22 (t, 6H).
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Supplementary Figure 1. Activity analysis of both N-terminally and C-terminally tagged Isoform A
and control Isoform B.

Supplementary Figure 2. Schematics of expression vectors with N-terminal and C-terminal
polyhistidine tags.

